How myo-inositol strengthens thyroid function

A molecule that helps the thyroid to reach its full potential

by Dr. Vedrana Högqvist Tabor

Myo-inositol, a molecule that is known to help reduce polycystic ovary syndrome (PCOS) symptoms, has recently been shown to potentially relieve Hashimoto’s symptoms as well.

PCOS and Hashimoto’s have many common genetic triggers and similar symptoms. In the general population, PCOS affects about 12 in 100 females of reproductive age (1–4). In our recent survey we found 40 in 100 people with Hashimoto’s are also diagnosed with PCOS. You can read more about the connection between the two conditions here.
What are your experiences? We would love to hear from you.

How does myo-inositol help?

For PCOS, inositol helps reduce acne and hirsutism (facial hair), restore a normal cycle, and combat insulin sensitivity (5,6). It regulates the levels of TSH and FSH (follicle stimulating hormone), as well as insulin (7).

In the case of thyroid hormones, myo-inositol helps thyroid-hormone-producing cells to become more efficient and faster at building T4 (8, 9). Myo-inositol balances thyroid hormones and reduces TSH as well as the TPO and Tg antibodies in the blood (8).

Myo-inositol dosage and health improvements

According to research papers, myo-inositol is used alone or together with selenium (8, 10, 11). Several research studies have shown that 600mg of myo-inositol is able to suppress symptoms in Hashimoto’s patients (10,11). It takes a longer time, about six month, before the effects of myo-inositol alone or together with selenium treatment are visible in blood tests (10,11).

As myo-inositol can cause certain side effects and should not be used in certain conditions, it is good to talk to your health care practitioner before using it.

References

1. Knochenhauer ES, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study,1998

2. Diamanti-Kandarakis E, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile, 1999

3. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), 2004

4. March WA, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria, 2010

5. Artini PG, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study, 2013

6. Unfer V, et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials, 2012

7. Papaleo E, et al. Contribution of myo-inositol to reproduction, 2009

8. Benvenga S, et al. Favorable effects of myo-inositol, selenomethionine or their combination on the hydrogen peroxide-induced oxidative stress of peripheral mononuclear cells from patients with Hashimoto’s thyroiditis: preliminary in vitro studies, 2017

9. Ohye H, et al. Dual oxidase, hydrogen peroxide and thyroid diseases, 2010

10. Nordio M, et al. Combined treatment with myo-inositol and selenium ensures euthyroidism in subclinical hypothyroidism patients with autoimmune thyroiditis, 2013

11. Nordio M, et al. Treatment with Myo-Inositol and Selenium Ensures Euthyroidism in Patients with Autoimmune Thyroiditis, 2017

Vedrana Högqvist Tabor